for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

武田薬品工業株式会社

4502.T

現在値

3,203.00JPY

変化

-4.00(-0.12%)

出来高

6,810,500

本日のレンジ

3,196.00

 - 

3,229.00

52週レンジ

3,157.00

 - 

4,365.00

∙ 約20分前の相場を表示しています。

適時開示

Immusoft Signs Research Collaboration And License Option Agreement With Takeda Pharmaceutical Co Ltd

Oct 13 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::IMMUSOFT - SIGNED RESEARCH COLLABORATION AND LICENSE OPTION AGREEMENT WITH TAKEDA PHARMACEUTICAL COMPANY LIMITED.IMMUSOFT - UNDER TERMS OF AGREEMENT, CO WILL RECEIVE AN UNDISCLOSED UPFRONT PAYMENT AND RESEARCH FUNDING SUPPORT.IMMUSOFT - ALSO ELIGIBLE TO RECEIVE FUTURE OPTION FEES AND MILESTONE PAYMENTS WITH A TOTAL POTENTIAL VALUE OF MORE THAN $900 MILLION.

Poseida Therapeutics Announces Research Collaboration With Takeda For Novel Non-Viral In Vivo Gene Therapies

Oct 12 (Reuters) - Poseida Therapeutics Inc <PSTX.O>::POSEIDA THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH TAKEDA FOR NOVEL NON-VIRAL IN VIVO GENE THERAPIES.POSEIDA THERAPEUTICS - PARTIES TO COLLABORATE TO INITIALLY DEVELOP UP TO SIX IN VIVO GENE THERAPY PROGRAMS UTILIZING CO'S NOVEL TECHNOLOGY PLATFORMS.POSEIDA THERAPEUTICS INC - TAKEDA ALSO HAS AN OPTION TO ADD TWO ADDITIONAL PROGRAMS TO COLLABORATION.POSEIDA THERAPEUTICS INC - TAKEDA IS OBLIGATED TO PROVIDE FUNDING FOR ALL COLLABORATION PROGRAM RESEARCH AND DEVELOPMENT COSTS.POSEIDA THERAPEUTICS INC - WILL RECEIVE AN UPFRONT PAYMENT OF $45 MILLION.POSEIDA THERAPEUTICS - WILL RECEIVE PRECLINICAL MILESTONES THAT TOGETHER COULD POTENTIALLY EXCEED $125 MILLION, IF MILESTONES FOR 6 PROGRAMS ARE ACHIEVED.POSEIDA - ELIGIBLE TO GET FUTURE MILESTONE PAYMENTS WITH POTENTIAL VALUE OF UP TO $2.7 BILLION IF MILESTONES FOR 6 PROGRAMS ARE ACHIEVED.POSEIDA THERAPEUTICS INC - ELIGIBLE TO RECEIVE UP TO $3.6 BILLION IF MILESTONES RELATED TO TWO OPTIONAL PROGRAMS ARE ALSO ACHIEVED.

Takeda Pharmaceutical Co Ltd Partners With Takeda To Develop Maralixibat For Rare Pediatric Liver Diseases In Japan

Sept 21 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::MIRUM PHARMACEUTICALS AND TAKEDA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE MARALIXIBAT FOR RARE PEDIATRIC LIVER DISEASES IN JAPAN.MIRUM PHARMACEUTICALS INC - TAKEDA WILL BE RESPONSIBLE FOR REGULATORY APPROVAL AND COMMERCIALIZATION OF MARALIXIBAT IN JAPAN.MIRUM PHARMACEUTICALS INC - TAKEDA WILL ALSO BE RESPONSIBLE FOR DEVELOPMENT, INCLUDING CONDUCTING CLINICAL STUDIES IN CHOLESTATIC INDICATIONS..

Takeda Pharmaceutical Co's Exkivity(Mobocertinib) Approved By U.S. FDA As The First Oral Therapy Specifically Designed For Patients With Egfr Exon20 Insertion+ Nsclc

Sept 15 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA’S EXKIVITY™ (MOBOCERTINIB) APPROVED BY U.S. FDA AS THE FIRST ORAL THERAPY SPECIFICALLY DESIGNED FOR PATIENTS WITH EGFR EXON20 INSERTION+ NSCLC.TAKEDA PHARMACEUTICAL CO - INDICATION IS APPROVED UNDER ACCELERATED APPROVAL BASED ON OVERALL RESPONSE RATE (ORR) AND DOR.TAKEDA PHARMACEUTICAL - EXKIVITY PRESCRIBING INFORMATION INCLUDES A BOXED WARNING FOR QTC PROLONGATION AND TORSADES DE POINTES.TAKEDA - FDA APPROVED THERMO FISHER SCIENTIFIC'S ONCOMINE DX TARGET TEST.TAKEDA PHARMACEUTICAL - EXKIVITY PRESCRIBING INFORMATION ALSO INCLUDES WARNINGS FOR INTERSTITIAL LUNG DISEASE/PNEUMONITIS, CARDIAC TOXICITY, DIARRHEA.TAKEDA - FDA APPROVED ONCOMINE DX TARGET TEST AS AN NGS COMPANION DIAGNOSTIC FOR EXKIVITY TO IDENTIFY NSCLC PATIENTS WITH EGFR EXON20 INSERTIONS.

Takeda Provides Update On Phase 3 PANTHER (Pevonedistat-3001) Trial

Sept 1 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PROVIDES UPDATE ON PHASE 3 PANTHER (PEVONEDISTAT-3001) TRIAL.TAKEDA PHARMACEUTICAL - PHASE 3 PANTHER STUDY DID NOT ACHIEVE PRE-DEFINED STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT OF EVENT-FREE SURVIVAL.TAKEDA PHARMACEUTICAL - TAKEDA WILL WORK WITH INVESTIGATORS WHO WILL DETERMINE MOST APPROPRIATE ACTION FOR EACH INDIVIDUAL PATIENT ENROLLED IN STUDY..

Joint Statement From Moderna, Takeda On Deaths Of Two Individuals Who Recently Received Moderna COVID-19 Vaccine

Aug 28 (Reuters) - Moderna Inc <MRNA.O>::JOINT STATEMENT FROM MODERNA AND TAKEDA.MODERNA-TAKEDA, MODERNA NOTIFIED ON AUG 28 JST, OF DEATHS OF 2 INDIVIDUALS WHO RECEIVED MODERNA COVID-19 VACCINE FOR INTRAMUSCULAR INJECTION IN JAPAN.MODERNA - AT THIS TIME, DO NOT HAVE ANY EVIDENCE THAT THESE DEATHS ARE CAUSED BY THE MODERNA COVID-19 VACCINE.MODERNA - TAKEDA AND MODERNA ARE WORKING WITH MINISTRY OF HEALTH, LABOUR AND WELFARE (MHLW) TO INVESTIGATE TWO DEATHS.MODERNA- ON AUGUST 26 JST, TAKEDA ANNOUNCED DECISION TO SUSPEND USE OF THREE LOTS OF MODERNA’S COVID-19 VACCINE IN JAPAN.MODERNA- THE SUSPENSION WAS IN ALIGNMENT WITH MHLW FOLLOWING REPORTS FROM VACCINATION SITES OF A FOREIGN SUBSTANCE FOUND IN VIALS.MODERNA- TO DATE, HAVE NO PRODUCT QUALITY COMPLAINTS RELATED TO PARTICULATE MATTER IN THE LOT RELATED TO UNFORTUNATE PASSING OF THE TWO INDIVIDUALS.MODERNA-TAKEDA REQUESTED MODERNA,MODERNA’S EUROPEAN CONTRACT MANUFACTURING ORGANIZATION,CONDUCT INVESTIGATION TO DETERMINE NATURE OF FOREIGN SUBSTANCE.MODERNA- AWARE OF UNOFFICIAL REPORTS THAT HAVE PROVIDED INITIAL INDICATION OF THE TYPE OF PARTICLE MATTER IN THE VIALS.MODERNA-IN PROCESS OF CONDUCTING INVESTIGATION, VIALS HAVE BEEN SENT TO QUALIFIED LAB FOR ANALYSIS;INITIAL FINDINGS WILL BE AVAILABLE EARLY NEXT WEEK.

Japan's ANA Says Secured More Moderna COVID-19 Vaccines To Replace Suspended Supply

Aug 27 (Reuters) - JAPAN'S ANA HOLDINGS: :SECURED MORE MODERNA COVID-19 VACCINES TO REPLACE SUSPENDED SUPPLY.TO RESUME VACCINATION ON SATURDAY AFTER SUSPENSION ON THURSDAY AND FRIDAY.Further company coverage: 9202.T.

Moderna Notified Of Cases Of Particulate Matter Seen In Vials Of Covid-19 Vaccine For A Lot Distributed In Japan

Aug 25 (Reuters) - Moderna Inc <MRNA.O>::MODERNA CONFIRMS HAVING BEEN NOTIFIED OF CASES OF PARTICULATE MATTER BEING SEEN IN DRUG PRODUCT VIALS ASSOCIATED WITH 1 LOT DISTRIBUTED IN JAPAN OF COVID-19 VACCINE.MODERNA SAYS HAS PUT ONE PRODUCT LOT DISTRIBUTED IN JAPAN AND TWO ADJACENT LOTS ON HOLD.MODERNA SAYS INVESTIGATING REPORTS OF CASES OF PARTICULATE MATTER BEING SEEN IN DRUG PRODUCT VIALS OF ITS COVID-19 VACCINE IN 1 LOT DISTRIBUTED IN JAPAN.MODERNA - BELIEVES MANUFACTURING ISSUE RELATED TO PARTICULATE MATTER SEEN IN VIALS OF COVID-19 VACCINE GENERATED IN ONE LINE USED AT CONTRACT MANUFACTURING SITE IN SPAIN.MODERNA - NO SAFETY/EFFICACY ISSUES HAVE BEEN IDENTIFIED RELATED TO CASES OF PARTICULATE MATTER SEEN IN DRUG PRODUCT VIALS OF COVID-19 VACCINE IN JAPAN.Further company coverage: MRNA.O. ((Reuters.Briefs@thomsonreuters.com;)).

Takeda Says Receives Decision By Irish Tax Appeals Commission Relating To Tax Assessment On Break Fee Shire Received From Abbvie

Aug 1 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES DECISION BY THE IRISH TAX APPEALS COMMISSION RELATING TO TAX ASSESSMENT ON BREAK FEE SHIRE RECEIVED FROM ABBVIE.TAKEDA PHARMACEUTICAL CO LTD - INTENDS TO CHALLENGE THIS OUTCOME THROUGH ALL AVAILABLE LEGAL MEANS.TAKEDA PHARMACEUTICAL CO LTD - QTRLY RESULTS WILL BE UPDATED TO REFLECT IMPACT OF DECISION WITH NO IMPACT ON CORE AND UNDERLYING FINANCIAL RESULTS.TAKEDA PHARMACEUTICAL CO LTD - DECISION WILL NOT IMPACT FULL YEAR FY2021 OUTLOOK FOR CORE OR UNDERLYING FINANCIAL RESULTS.

Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (Sot) Types Supports Efficacy Of Maribavir Over Conventional Therapies In Post-Transplant Recipients With Cytomegalovirus (

June 7 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::PHASE 3 CLINICAL TRIAL SUBGROUP ANALYSIS ACROSS SOLID ORGAN TRANSPLANT (SOT) TYPES SUPPORTS EFFICACY OF MARIBAVIR OVER CONVENTIONAL THERAPIES IN POST-TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS (CMV) INFECTION (REFRACTORY, WITH OR WITHOUT RESISTANCE).TAKEDA PHARMA - MORE THAN 3 TIMES AS MANY LUNG TRANSPLANT RECIPIENTS WITH R/R CMV INFECTION TREATED WITH MARIBAVIR ACHIEVED CONFIRMED CMV VIREMIA CLEARANCE.TAKEDA PHARMA - MORE THAN 1.5 TIMES AS MANY KIDNEY TRANSPLANT RECIPIENTS WITH R/R CMV INFECTION TREATED WITH MARIBAVIR ACHIEVED CONFIRMED CMV VIREMIA CLEARANCE VERSUS THOSE ON CONVENTIONAL THERAPIES.TAKEDA PHARMACEUTICAL CO LTD - FINDINGS REINFORCE RESULTS FROM OVERALL TRIAL POPULATION WHICH SHOWED STUDY MET ITS PRIMARY ENDPOINT.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up